TY - JOUR
T1 - Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group
AU - Dorhout Mees, Sanne M
AU - MASH-II study group
AU - Al-Shahi Salman, Rustam
PY - 2008
Y1 - 2008
N2 - Delayed cerebral ischemia (DCI) is an important cause of poor outcome after aneurysmal subarachnoid hemorrhage (SAH). Magnesium is a neuroprotective agent that acts as an NMDA-receptor antagonist and a calcium channel blocker. In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.
AB - Delayed cerebral ischemia (DCI) is an important cause of poor outcome after aneurysmal subarachnoid hemorrhage (SAH). Magnesium is a neuroprotective agent that acts as an NMDA-receptor antagonist and a calcium channel blocker. In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.
U2 - 10.1111/j.1747-4949.2008.00168.x
DO - 10.1111/j.1747-4949.2008.00168.x
M3 - Article
C2 - 18705917
VL - 3
SP - 63
EP - 65
JO - International Journal of Stroke
JF - International Journal of Stroke
SN - 1747-4930
IS - 1
ER -